中华皮肤科杂志 ›› 2019, Vol. 52 ›› Issue (5): 337-339.doi: 10.3760/cma.j.issn.0412-4030.2019.05.012

• 药物与临床 • 上一篇    下一篇

枸地氯雷他定治疗慢性荨麻疹的疗效及对血清白细胞介素23和33、趋化因子PARC/CCL-18的影响

徐延峰1    杜威萍2    骆志成3    沈海莲1   

  1. 1甘肃省武威肿瘤医院皮肤科  733000；2甘肃省武威市人民医院皮肤科  733000；3兰州大学第二医院皮肤科  730030
  • 收稿日期:2018-10-29 修回日期:2019-03-27 出版日期:2019-05-15 发布日期:2019-04-30
  • 通讯作者: 徐延峰 E-mail:920646449@qq.com
  • 基金资助:
    甘肃省武威市科技计划项目（WW170216）

Efficacy of desloratadine citrate disodium in the treatment of chronic urticaria and its effect on serum interleukin-23, interleukin-33 and PARC/CCL-18

Xu Yanfeng1, Du Weiping2, Luo Zhicheng3, Shen Hailian1   

  1. 1Department of Dermatology, Wuwei Oncology Hospital, Wuwei 733000, Gansu, China; 2Department of Dermatology, Wuwei People′s Hospital, Wuwei 733000, Gansu, China; 3Department of Dermatology, Lanzhou University Second Hospital, Lanzhou 730030, China
  • Received:2018-10-29 Revised:2019-03-27 Online:2019-05-15 Published:2019-04-30
  • Contact: Xu Yanfeng E-mail:920646449@qq.com
  • Supported by:
    Wuwei Science and Technology Planning Project of Gansu Province （WW170216）

PDF

0

赞

摘要： 【摘要】 目的 比较枸地氯雷他定和氯雷他定治疗慢性荨麻疹（CU）的疗效及对血清白细胞介素（IL）-23、IL-33及肺部活化调节趋化因子/趋化因子配体18（PARC/CCL-18）的影响。方法 选择 2013年1月至 2016年 12月在本院接受治疗的CU患者120例，按随机数字表法分为研究组（60例）和对照组（60例），研究组口服枸地氯雷他定片8.8 mg每日1次，对照组口服氯雷他定片10 mg每日1次，两组均治疗28 d，对比两组疗效以及治疗前后血清IL-23、IL-33及趋化因子PARC/CCL-18水平的变化。分别采用t检验和χ2检验比较两组间指标差异。结果 研究组有效53例（88.33%），对照组有效37例（61.67%），两组比较，χ2 = 15.35，P＜0.01。研究组治疗后血清IL-23、IL-33、PARC/CCL-18水平分别下降至（87.72 ± 22.16） ng/L、（95.94 ± 18.27） ng/L、（85.93 ± 27.34） μg/L，均低于对照组［（104.21 ± 32.05） ng/L、（106.27 ± 20.93） ng/L、（95.72 ± 30.28） μg/L］，t值分别为3.26、 4.03、3.93，均P < 0.05。两组不良反应发生率差异无统计学意义（P = 0.298）。结论 枸地氯雷他定治疗CU可显著改善临床症状，安全性好，可能的机制为降低机体免疫反应，减少趋化因子对炎性细胞的趋化作用。

关键词: 氯雷他定, 荨麻疹, 白细胞介素23, 白细胞介素33, 枸地氯雷他定, PARC/CCL-18

Abstract: 【Abstract】 Objective To compare the efficacy of desloratadine citrate disodium versus loratadine in the treatment of chronic urticaria （CU）, and to evaluate their effect on serum interleukin （IL）-23, IL-33 and pulmonary and activation-regulated chemokine/CC chemokine ligand 18 （PARC/CCL-18）. Methods From January 2013 to December 2016, 120 CU patients treated in Department of Dermatology, Wuwei Oncology Hospital were enrolled into this study, and divided into study group and control group by using a random number table. Patients in the study group took oral desloratadine citrate disodium tablets 8.8 mg once a day, and patients in the control group took loratadine tablets 10 mg once a day. The treatment lasted 28 days. The therapeutic effect was compared between the two groups, and changes in serum levels of IL-23, IL-33 and PARC/CCL-18 were compared before and after treatment. Statistical analysis was carried out by using two-sample t test and chi-square test for comparing indices between the two groups. Results The response rate was significantly higher in the study group （88.33%, 53/60） than in the control group （［61.67%, 37/60］, χ2 = 15.352, P < 0.01）. After the treatment, the serum levels of IL-23, IL-33 and PARC/CCL-18 in the study group significantly decreased to （87.72 ± 22.16） ng/L, （95.94 ± 18.27） ng/L, （85.93 ± 27.34） μg/L respectively, which were all lower than those in the control group （［104.21 ± 32.05］ ng/L, ［106.27 ± 20.93］ng/L, ［95.72 ± 30.28］ μg/L, respectively; t = 3.264, ?4.034, 3.934 respectively, P = 0.020, 0.006, 0.015 respectively）. No significant difference was observed in the incidence of adverse reactions between the study group and control group （P = 0.298）. Conclusion Desloratadine citrate disodium can markedly improve the clinical symptoms of CU with favorable safety, likely by inhibiting the immune response of the body and reducing the effect of chemokines on the chemotaxis of inflammatory cells.

Key words: Loratadine, Urticaria, Interleukin?23, Interleukin?33, Desloratadine citrate disodium, PARC/CCL-18